{"id":505483,"date":"2021-06-22T09:05:32","date_gmt":"2021-06-22T13:05:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/"},"modified":"2021-06-22T09:05:32","modified_gmt":"2021-06-22T13:05:32","slug":"abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/","title":{"rendered":"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada"},"content":{"rendered":"

<\/p>\n

AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada<\/b><\/p>\n

130,000-square-foot Vancouver facility aims to accelerate the development of antibody-based therapies for an array of medical conditions.<\/i><\/p>\n

VANCOUVER, British Columbia–(BUSINESS WIRE<\/a>)–
\nAbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera\u2019s capabilities in bringing new antibody therapies to clinical trials, supporting Canada\u2019s efforts to respond quickly and effectively to future pandemics and providing AbCellera\u2019s partners with a full solution for accelerating their programs from a drug target to the submission of an Investigational New Drug (IND) application.\n<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210622005425\/en\/<\/a><\/p>\n

\"Rendering<\/p>\n

Rendering of AbCellera\u2019s GMP Facility at 900-Block Evans Avenue. Images provided by Chernoff Thompson Architects<\/p>\n<\/div>\n

\n\u201cWe envision AbCellera as a premier destination for the brightest and most creative minds, for people who seek challenges and who want to work at the leading edge,\u201d said Murray McCutcheon, Ph.D., Vice President of Corporate Development at AbCellera. \u201cOur recently announced headquarters and new GMP facility will empower entirely new capabilities and jobs in Canada that we believe will make our communities stronger, bring treatments to patients sooner, and leave a legacy of innovation.\u201d\n<\/p>\n

\nThis announcement follows AbCellera\u2019s April groundbreaking<\/a> on a new global headquarters in Vancouver. The 380,000-square-foot headquarters on 4th Avenue between Columbia and Manitoba Streets will be within walking distance of the new GMP manufacturing facility. The new GMP facility will be built on what is currently a vacant two-acre site, and the planned building will house laboratory, office, GMP protein biologic manufacturing, and warehouse space. Design efforts are already underway and groundbreaking is scheduled for later this year.\n<\/p>\n

\nIn parallel with the construction of the new facility, AbCellera is also building up an internal Chemistry Manufacturing and Controls (CMC) development organization \u2013 the team of scientists and engineers responsible for developing the manufacturing processes for antibody therapeutics. CMC and GMP manufacturing capabilities will extend AbCellera\u2019s competencies and, when combined with AbCellera\u2019s world-leading technology stack for antibody discovery, will enable AbCellera to support partners to move rapidly and seamlessly from discovery to the clinic.\n<\/p>\n

\n\u201cAbCellera has already redefined the speed of antibody drug discovery, and the addition of CMC and GMP capabilities gives us the ability to fully integrate lead therapeutic selection, moving key choices earlier, and aligning teams to make a seamless arc of drug development for our partners,\u201d said Bo Barnhart, Ph.D., Scientific Director at AbCellera. \u201cWe are building a unique team that includes innovative CMC Development leaders, deeply integrated with Discovery and Translational Research, all focused on selecting and developing better therapeutics to go from antibody discovery to fill-finish in a year.\u201d\n<\/p>\n

\nThe facility is scheduled to be ready for GMP manufacturing in early 2024, and at full capacity will employ hundreds of highly skilled scientific personnel. AbCellera anticipates adding hundreds of employees to its current workforce of nearly 300 people over the next few years. The development of the new GMP manufacturing facility is funded in part by a US$125.6-million grant from the Canadian government\u2019s Strategic Innovation Fund (SIF) to support AbCellera\u2019s work and Canada\u2019s ability to respond quickly to future pandemics.\n<\/p>\n

\n\u201cI am pleased to see AbCellera participating in our government\u2019s effort to reverse a four-decade decline in Canada\u2019s domestic capacity,\u201d said the Honourable Fran\u00e7ois-Philippe Champagne, Minister of Innovation, Science and Industry. \u201cThis is an important step toward improving Canada\u2019s pandemic preparedness, and a driver for our economic recovery.\u201d\n<\/p>\n

\nAbCellera is at the forefront of the global COVID-19 response, with its discovery of bamlanivimab, the world\u2019s first monoclonal antibody therapy for COVID-19 to be authorized for emergency use by both the U.S. FDA and Health Canada. More than 400,000 doses of bamlanivimab have been administered worldwide, keeping more than 22,000 patients out of hospital, and saving at least 11,000 lives. AbCellera has also discovered a second antibody, LY-CoV1404, that is being advanced by Eli Lilly & Company to address emerging and future variants. This antibody has been shown to be effective against all currently circulating variants of concern and entered clinical trials in May.\n<\/p>\n

About AbCellera Biologics Inc.<\/b><\/p>\n

\nAbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com<\/a>.\n<\/p>\n

AbCellera Forward-looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.\n<\/p>\n

\nIn some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.\n<\/p>\n

\nSource: AbCellera Biologics Inc.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210622005425\/en\/<\/a><\/span><\/p>\n

Inquiries
\n<\/b>
Media: Jessica Yingling, Ph.D.; media@abcellera.com<\/a>, +1(236)521-6774
\n
Business Development: Kevin Heyries, Ph.D.; bd@abcellera.com<\/a>, +1(604)559-9005
\n
Investor Relations: Melanie Solomon; ir@abcellera.com<\/a>, +1(778)729-9116\u2003\n<\/p>\n

KEYWORDS:<\/b> United States North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Other Manufacturing Research Medical Supplies Infectious Diseases Genetics Manufacturing Biotechnology Pharmaceutical Health Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n
Photo<\/b><\/font><\/td>\n<\/tr>\n
\"Photo\"<\/td>\n<\/tr>\n
Rendering of AbCellera\u2019s GMP Facility at 900-Block Evans Avenue. Images provided by Chernoff Thompson Architects<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada 130,000-square-foot Vancouver facility aims to accelerate the development of antibody-based therapies for an array of medical conditions. VANCOUVER, British Columbia–(BUSINESS WIRE)– AbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera\u2019s capabilities in bringing new antibody therapies to clinical trials, supporting Canada\u2019s efforts to respond quickly and effectively to future pandemics and providing AbCellera\u2019s partners with a full solution for accelerating their programs from a drug … <\/p>\n

Continue reading “AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-505483","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada 130,000-square-foot Vancouver facility aims to accelerate the development of antibody-based therapies for an array of medical conditions. VANCOUVER, British Columbia–(BUSINESS WIRE)– AbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera\u2019s capabilities in bringing new antibody therapies to clinical trials, supporting Canada\u2019s efforts to respond quickly and effectively to future pandemics and providing AbCellera\u2019s partners with a full solution for accelerating their programs from a drug … Continue reading "AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-22T13:05:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20210622005425\/en\/886698\/4\/AbC_GMPRendering.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada\",\"datePublished\":\"2021-06-22T13:05:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/\"},\"wordCount\":1206,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210622005425\\\/en\\\/886698\\\/4\\\/AbC_GMPRendering.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/\",\"name\":\"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210622005425\\\/en\\\/886698\\\/4\\\/AbC_GMPRendering.jpg\",\"datePublished\":\"2021-06-22T13:05:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210622005425\\\/en\\\/886698\\\/4\\\/AbC_GMPRendering.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20210622005425\\\/en\\\/886698\\\/4\\\/AbC_GMPRendering.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/","og_locale":"en_US","og_type":"article","og_title":"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada - Market Newsdesk","og_description":"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada 130,000-square-foot Vancouver facility aims to accelerate the development of antibody-based therapies for an array of medical conditions. VANCOUVER, British Columbia–(BUSINESS WIRE)– AbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera\u2019s capabilities in bringing new antibody therapies to clinical trials, supporting Canada\u2019s efforts to respond quickly and effectively to future pandemics and providing AbCellera\u2019s partners with a full solution for accelerating their programs from a drug … Continue reading \"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-22T13:05:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20210622005425\/en\/886698\/4\/AbC_GMPRendering.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada","datePublished":"2021-06-22T13:05:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/"},"wordCount":1206,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20210622005425\/en\/886698\/4\/AbC_GMPRendering.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/","name":"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20210622005425\/en\/886698\/4\/AbC_GMPRendering.jpg","datePublished":"2021-06-22T13:05:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20210622005425\/en\/886698\/4\/AbC_GMPRendering.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20210622005425\/en\/886698\/4\/AbC_GMPRendering.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-continues-expansion-and-strengthens-future-pandemic-preparedness-with-first-of-its-kind-gmp-manufacturing-facility-for-therapeutic-antibodies-in-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/505483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=505483"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/505483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=505483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=505483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=505483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}